EGFR and non-small cell lung carcinoma: Interestingly, due to its role in binding to the extracellular domains of EGFR and MET receptors, amivantamab is demonstrating a favorable toxicity profile against both EGFR exon 20 insertion tumors in pre-treated patients with NSCLC and in those harboring classical EGFR mutations.